Editing Extracorporeal membrane oxygenation (section)

=== Outcomes ===
Early studies had shown survival benefit with use of ECMO for people in acute respiratory failure especially in the setting of [[acute respiratory distress syndrome]].<ref name="pmid9315812" /><ref name="pmid9310799" /> A registry maintained by ELSO of nearly 51,000 people that have received ECMO has reported outcomes with 75% survival for neonatal respiratory failure, 56% survival for pediatric respiratory failure, and 55% survival for adult respiratory failure.<ref>{{cite journal | vauthors = Thiagarajan RR, Barbaro RP, Rycus PT, Mcmullan DM, Conrad SA, Fortenberry JD, Paden ML | title = Extracorporeal Life Support Organization Registry International Report 2016 | journal = ASAIO Journal | volume = 63 | issue = 1 | pages = 60–67 | date = 2017-04-01 | pmid = 27984321 | doi = 10.1097/MAT.0000000000000475 | s2cid = 205758344 }}</ref> Other observational and uncontrolled clinical trials have reported survival rates from 50 to 70%.<ref name="pmid15383787"/><ref name="pmid19768656"/> These reported survival rates are better than historical survival rates.<ref name="pmid9351722"/><ref name="pmid9556124"/><ref name="pmid10598597"/> Even though ECMO is used for a range of conditions with varying mortality rates, early detection is key to prevent the progression of deterioration and increase survival outcomes.<ref name = "Lich_2004">{{cite book | vauthors = Lich B |title=The Manual of Clinical Perfusion |date=2004 |publisher=Perfusion.com |location=Fort Myers, Florida |isbn=978-0-9753396-0-2 |edition=2nd }}</ref>

In the [[United Kingdom]], veno-venous ECMO deployment is concentrated in designated ECMO centers to potentially improve care and promote better outcomes.